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Abstract
Background: In a genome-wide association study performed in the Framingham Offspring
Cohort, individuals homozygous for the rs7566605 C allele located upstream of insulin-induced
gene 2 (INSIG2) were reported to incur an increased risk of obesity. This finding was later
replicated in four out of five populations examined. The goal of the study reported here was to
assess the role of the INSIG2 single nucleotide polymorphism (SNP) in susceptibility to obesity in
the prospective longitudinal Atherosclerosis Risk in Communities (ARIC) study (n = 14,566) and
in three other cohorts: the Coronary Artery Risk Development in Young Adults (CARDIA) study
(n = 3,888), the Genetic Epidemiology Network of Arteriopathy (GENOA) study (n = 4,766), and
extremely obese and lean individuals ascertained at the University of Ottawa (n = 1,502). The
combined study sample is comprised of 24,722 white, African-American, and Mexican-American
participants.
Methods: Differences in mean body mass index (BMI) and other anthropometric measures
including weight, waist circumference, and waist-to-hip ratio were assessed by a general linear
model in individuals categorized by INSIG2 rs7566605 genotype. Multivariable logistic regression
was used to predict the risk of obesity (BMI ≥ 30 kg/m2).
Results: There was no discernable variation in the frequencies of the three INSIG2 SNP genotypes
observed between white, Hispanic, and African-American obese individuals and non-obese study
subjects. When the relationship between rs7566605 and BMI considered either as a categorical
variable or a continuous variable was examined, no significant association with obesity was found
for participants in any of the four study populations or in a combined analysis (p = 0.38) under a
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obesity-related quantitative traits except for a reduced waist-to-hip ratio in white ARIC study
participants homozygous for the C allele, and an increased waist-to-hip ratio in African-Americans
in the ARIC cohort with the same genotype (p = 0.04 and p = 0.01, respectively). An association
with waist-to-hip ratio was not seen when the combined study sample was analyzed (p = 0.74).
Conclusion: These results suggest that the INSIG2 rs7566605 variant does not play a major role
in determining obesity risk in a racially and ethnically diverse sample of 24,722 individuals from four
cohorts.
Background
Obesity results from an imbalance between food intake and
energy expenditure, and is a major risk factor for many of the
chronic diseases of adulthood including hypertension, type
2 diabetes, coronary heart disease and stroke [1,2]. Although
the results of twin and adoption studies provide strong sup-
port for a genetic influence on body weight [3-5], mutations
causing monogenic forms of obesity are rare in the popula-
tion [6], and major genes contributing to common obesity
have not been described. In addition, interaction between
genes and environment is suggested by an age-adjusted prev-
alence of 32.9% reported for American adults with a BMI ≥
30 kg/m2 in 2002–2004, while only 15% met this criterion
in the 1976–1980 National Health Examination Survey
[7,8]. Recent genetic studies have focused on unbiased
genome-wide associations studies (GWAS) of the relation-
ship between large numbers of common genetic polymor-
phisms measured simultaneously and disease risk. The
development of high-density genotyping technology and the
completion of the HapMap resource [9] have facilitated this
approach, and enabled the successful detection of SNPs with
moderate effects that contribute to common variation in
obesity [10-18].
Herbert et al. identified a genetic variant near the INSIG2
locus associated with obesity as assessed by a BMI ≥ 30 kg/
m2 in a GWAS carried out in participants in the Framing-
ham Heart Study [19]. This finding was subsequently rep-
licated in four of five additional populations. Since the
homozygous CC genotype conferring susceptibility was
found to be present in approximately 10% of the individ-
uals studied, the authors speculated that although the
rs7566605 polymorphism has a moderate influence on
the risk for obesity (pooled odds ratio (OR) = 1.22, 95%
confidence interval (CI) = 1.05–1.42, p = 0.0080), there
may be a considerable impact of this gene on public
health due to the high frequency of the allele in the gen-
eral population. Similarly, when the rs7566605 variant
was subsequently genotyped in nine additional cohorts
from multiple ethnicities the association with BMI was
reproduced in only five of the study samples suggesting
that the effect of the variant might differ between popula-
tions [20]. INSIG2 was also independently identified as a
genetic determinant of obesity in a genome-wide associa-
tion study carried out in 1,000 unrelated Caucasian adults
of Northern European origin [15]. We, therefore, assessed
the effect of rs7566605 on obesity risk in individuals
enrolled in the Atherosclerosis Risk in Communities
(ARIC) study [21], the Coronary Artery Risk Development
in Young Adults (CARDIA) study [22,23], the Genetic Epi-
demiology Network of Arteriopathy (GENOA) study [24],
and two cohorts of extremely obese and lean white indi-
viduals ascertained at the University of Ottawa [25].
INSIG2 maps to chromosome 2q14, and encodes a 225-
amino acid protein that participates in two pathways impli-
cated in the regulated synthesis of cholesterol, fatty acids,
and triglycerides in the liver and other organs. The first of
these entails the sterol-dependent cleavage of two transcrip-
tion factors, sterol regulatory element-binding proteins 1
and 2, found in the endoplasmic reticulum. If sterols are
present, INSIG2 blocks lipid synthesis by preventing the
translocation of the transcription factors to the nucleus and
transcription of target genes declines [26-31]. INSIG2 can
also bind to the enzyme 3-hydroxy-3-methylglutaryl coen-
zyme A reductase (HMG CoA reductase) which catalyzes the
rate-limiting step in cholesterol biosynthesis. Following
interaction with INSIG2, HMG CoA reductase is ubiquiti-
nated and rapidly degraded in the proteasome so that choles-
terol synthesis is inhibited [32-35]. A role for Insig-2 in vivo
was later established using an animal model when overex-
pression of the Insig-2 cDNA in Zucker diabetic fatty rats was
shown to decrease the levels of triacylglycerols in the liver
and plasma when compared to uninfected littermate con-
trols [36].
Although sequence variation at the INSIG2 locus that
could lead to differences in the level of INSIG2 between
individuals might plausibly contribute to variation in risk
for obesity, we report here that there was no increased sus-
ceptibility for homozygous carriers of the rs7566605
minor C allele in an ethnically and racially diverse sample
of 24,722 individuals belonging to four cohorts.
Methods
Atherosclerosis Risk in Communities (ARIC) Study
The ARIC Study is a prospective longitudinal investigation
of the development of atherosclerosis and its clinicalPage 2 of 9
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at baseline selected by probability sampling from four dif-
ferent communities in the United States. The participants
were residents of Forsyth County, NC; Jackson, MS (Afri-
can-Americans only); the northwestern suburbs of Minne-
apolis, MN; or Washington County, MD at the time of
recruitment in 1986–1989. Four sequential examinations
have been carried out every three years (exam 1, 1987–
1989; exam 2, 1990–1992; exam 3, 1993–1995; and exam
4, 1996–1999), and subjects are contacted annually to
update their medical histories between examinations.
Subjects were excluded from this analysis if they were Afri-
can-American but not from Jackson or Forsyth County, if
they were neither African-American nor white, if they had
restricted use of their DNA, or if they were missing INSIG2
genotype or BMI. The final study sample consisted of
14,566 participants (n = 3,870 African-American, 10,696
white). An additional 7 individuals were excluded for
missing data in the analysis of weight, waist circumfer-
ence, and waist-to-hip ratio. All individuals enrolled in
the ARIC study provided written informed consent, and
the study design and methods were approved by institu-
tional review boards at the collaborating medical centers.
A detailed description of the ARIC study has been
reported previously [21].
Coronary Artery Risk Development in Young Adults 
(CARDIA) Study
The CARDIA study was designed to examine the develop-
ment of heart disease in 5,115 African-American and
white women aged 18–30 years at the time of recruitment
in 1986. The participants were selected in Birmingham,
AL; Chicago, IL; Minneapolis, MN; and Oakland, CA so
that there would be approximately equal numbers of sub-
jects in subgroups of race, gender, education, and age.
Individuals were excluded from this analysis if they were
missing either INSIG2 genotype data or BMI. The final
study sample consisted of 3,888 participants (n = 1,887
African-American, 2,001 white). An additional 6 individ-
uals were excluded for missing data in the analysis of
weight, waist circumference, and waist-to-hip ratio. The
results of the baseline examination have been previously
reported [37]. Six examinations have been conducted
through year 20 (2005–2006). Written informed consent
was obtained from the participants at each examination,
and all study protocols were approved by the institutional
review boards of the participating institutions.
Genetic Epidemiology Network of Arteriopathy (GENOA) 
Study
The goal of the GENOA study is to localize, identify, and
evaluate common variation in genes involved in deter-
mining interindividual differences in blood pressure and
its associated cardiac and renal complications. GENOA
consists of groups of siblings recruited from three field
centers: the field center in Jackson, MS recruited 1,228
African-Americans from 553 sibships; the field center in
Rochester, MN recruited 1,022 Non-Hispanic whites from
435 sibships; and the field center in Starr County, TX
recruited 954 Mexican-Americans from 363 sibships. For
the Non-Hispanic white and African-American partici-
pants, sibships were recruited that contained at least two
siblings with essential hypertension diagnosed before the
age of 60. Hypertension status was defined by systolic
blood pressure >140 mm Hg or diastolic blood pressure
>90 mm Hg, or use of medication for hypertension. For
the Mexican-Americans, sibships were selected that con-
tained at least two siblings with type 2 diabetes. Diabetes
was defined by a fasting serum glucose ≥ 126 mg/dl, or
current use of hypoglycemic medication or insulin that
was documented at examination in the clinic, or diabetes
reported on questionnaires. For all three ethnic groups,
additional siblings without disease were also invited to
participate. Sampling details, the clinic and laboratory
protocols, and baseline characteristics have been
described by Daniels et al. [38]. Study participants were
excluded from this analysis if they were missing INSIG2
genotype or BMI. The final study sample consisted of
4,766 participants (n = 1,731 African-American, 1,421
white, 1,614 Hispanic). An additional 4 individuals were
excluded for missing data in the analysis of weight, waist
circumference, and waist-to-hip ratio. All GENOA partici-
pants provided written informed consent after approval
by appropriate institutional review boards for the protec-
tion of human subjects.
University of Ottawa
Two cohorts of extremely obese white men and women
were ascertained through the University of Ottawa Weight
Management Clinic and the Heart Institute Lipid Clinic
(cohort 1, n = 380, mean BMI 49.0 kg/m2, >95th percentile
adjusted for age and sex; cohort 2, n = 382, mean BMI
37.1 kg/m2) [25]. Two cohorts of apparently healthy
white men and women recruited from the community
who participated in a study of leanness served as the
respective comparison groups (cohort 1, n = 378, mean
BMI 19.4 kg/m2, <10th percentile adjusted for age and sex;
cohort 2, n = 381, mean BMI 20.9 kg/m2). Individuals
were excluded from this analysis if they were missing
INSIG2 genotype or if they were obese members of cohort
2 whose BMI < 29.5 kg/m2. The study was approved by the
institutional review boards of the University of Ottawa
Heart Institute and the Ottawa Hospital, and informed
written consent was obtained from all participants.
Obesity and Anthropometric Measurements
BMI was calculated as weight in kilograms/(height in
meters)2 and obesity was defined as BMI ≥ 30 using crite-
ria established by the World Health Organization [39].
Waist circumference was determined as waist girth in cm.Page 3 of 9
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Waist-to-hip ratio was calculated as waist girth in cm/hip
girth in cm.
Genotype Determination
Genotyping of the INSIG2 rs7566605 polymorphism was
performed using the TaqMan assay (Applied Biosystems,
Foster City, CA). Sequences for primers and TaqMan
probes are available upon request. Allele detection was
performed using the ABI Prism 7700 Sequence Detection
System (Applied Biosystems). The genotyping success rate
was 96.3% for the ARIC cohort, 97.1% for GENOA study
participants, and 96.5% for CARDIA subjects. The accord-
ance between blind duplicates was 99%, 100%, and
100%, respectively. The assay was performed once for
each sample since the final genotype call rate in each
study population exceeded 90%. The percentage of miss-
ing data for the Ottawa cohorts was 0.7%.
Statistical Analysis
All statistical analyses were performed using Stata 9 soft-
ware (StataCorp, College Station, TX). Hardy-Weinberg
equilibrium was tested using a χ2 goodness-of-fit test for
all individuals within each population sample after strati-
fication by race. The proportions, means and standard
deviations were calculated for established risk factors for
obesity for both the obese study participants and for the
comparison groups. Multivariable logistic regression was
used to evaluate the relationship between obesity case sta-
tus and the INSIG2 alleles under a recessive genetic
model. Prevalence odds ratios (OR) were adjusted for age
and gender as covariates known to be correlated with
anthropometric measures [8]. Cohort-specific results for
the analysis of obesity were combined using the Mantel-
Haenszel method. General linear models adjusted for age
and gender were used to assess mean differences in BMI
and other quantitative measures of body size and compo-
sition among INSIG2 rs7566605 genotypes. For each of
the three ethnic groups included in the GENOA study, one
sibling was picked at random from each family and the
results of all statistical analyses carried out for the smaller
study groups were compared with those obtained for the
total stratum. In all cases the results were similar so that
no further adjustment for family relationship was per-
formed. Power analyses for obesity studied as a categorical
variable and for the obesity-related quantitative traits were
conducted with the program Quanto http://
hydra.usc.edu/GxE/ using a fixed sample size for the par-
ticipants in each cohort stratified by race, a p-value of
0.05, and the allele frequencies and prevalence of the rel-
evant phenotype in each study sample. The results of all
statistical analyses are reported separately by self-reported
racial group. A p-value < 0.05 was considered statistically
significant.
Results
A description of the study sample divided into case and
comparison groups on the basis of obesity (BMI ≥ 30 kg/
m2) and stratified by racial group is shown in Table 1. The
allele and genotype frequencies for the INSIG2 polymor-
phism were in agreement with Hardy-Weinberg equilib-
rium expectations in each of our study populations. In
African-American, white, and Hispanic obese individuals,
there was no discernable difference in the frequencies of
the three INSIG2 SNP genotypes when compared to non-
obese study subjects (Table 1). When the relationship
between the rs7566605 variant and BMI considered either
as a categorical variable or a continuous variable was stud-
ied, no significant association with obesity was found for
participants in any of the four cohorts or in a combined
analysis of all of the study groups (p = 0.38; p = 0.88 for
Mantel-Haenszel test of homogeneity) (Table 2). Weight,
waist circumference, and waist-to-hip ratio were also
examined in three of the cohorts after stratification by race
(Tables 2 and 3). There were no significant mean differ-
ences observed among INSIG2 rs7566605 genotypes for
these anthropometric measurements with the exception
of a significant association for reduced waist-to-hip ratio
for white ARIC study participants with the INSIG2 CC
genotype, and for an increased waist-to-hip ratio for Afri-
can-Americans in the ARIC cohort carrying the same
allele. After combining all of the study participants and
adjusting for age, gender, race, and study, there was no sig-
nificant association between rs7566605 and any of the
obesity-related quantitative traits (Tables 2 and 3).
Discussion
The role of INSIG2 rs7566605 as a determinant of obesity
risk was investigated in a sample of 24,722 individuals
belonging to four different cohorts and a significant asso-
ciation was not found under a recessive genetic model.
Herbert et al. identified a genetic variant (rs7566605) 10
kb upstream of INSIG2 that was associated with obesity as
assessed by a BMI ≥ 30 kg/m2 in participants in the Fram-
ingham Heart Study. This finding was then replicated in
four of five additional populations including individuals
of Western European ancestry, African-Americans, and
children [19]. However, the absence of an association
between rs7566605 and BMI levels when DNA samples
from the Nurses Health Study cohort were genotyped sug-
gested that the SNP may have variable effects in different
populations. The initial association with measures of
body size has subsequently been reproduced in some
[15,20,40-43] but not all cohorts [44-56]. In one of three
of the earliest studies designed to replicate this finding,
Dina et al. reported a lack of association between
rs7566605 and either BMI or obesity under a recessive
model in 4,998 unrelated middle-aged French partici-
pants in the Donne Epidemiologiques sur le SyndromePage 4 of 9
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no evidence of association between the sequence variant
and obesity in two other large studies of unrelated Euro-
pean adults when 4,916 individuals in the European Pro-
spective Investigation of Cancer (EPIC) Norfolk study or
1,683 subjects in the Medical Research Council (MRC) Ely
study were genotyped [46]. Although Rosskopf et al. did
not observe any association between the INSIG2 variant
and either obesity or BMI when the entire Study of Health
in Pomerania (SHIP) cohort consisting of 4,310 unrelated
German individuals was assessed, a subgroup analysis of
2,701 overweight individuals in SHIP showed that both
the mean BMI and risk of being obese was increased for
rs7566605 CC homozygotes when compared to those
with the GC and GG genotypes. Based on these results, the
authors speculated that since INSIG2 is a regulator of
insulin-mediated fatty acid synthesis [57], the effect of the
rs7566605 variant might be stronger under conditions of
increased insulin stimulation, and might explain the fail-
ure to find an association in the Nurses' Health Study
where the mean BMI was lower than in the other study
samples [19,47]. A similar suggestion was made by Hall et
al. to explain the lack of replication of an association
between the INSIG2 variant and obesity-related pheno-
types in 1,428 members of 248 British families where
about half of the cohort was overweight [44]. However,
no difference in the distribution of rs7566605 genotype
frequencies, or association with measures of body compo-
sition including BMI, waist circumference, waist-to-hip
ratio, and percentage body fat was found when 1,026
severely obese patients with a mean BMI of 46.0 kg/m2
were compared with 818 population-based controls from
Utah [53]. Similarly, no association with overweight,
obesity, or obesity-related quantitative traits was reported
in a combined sample of 18,014 Danish subjects from
four cohorts, or in an obese subgroup of 3,878 subjects
with a mean BMI of 32.8 kg/m2[52].
There was also no consistent evidence that the INSIG2
polymorphism is a determinant of obesity risk in studies
including individuals of non-European descent. No asso-
ciation between rs7566605 and BMI or measures of obes-
ity was found in two separate cohorts in India [48], a
group of 747 patients with type 2 diabetes that included
Afro-Caribbean and Indian subjects [49], or in three Japa-
nese cohorts [50,51,54], while a significant association
with obesity was found for 908 Japanese patients with a
mean BMI ≥ 30 kg/m2 when compared to 1,495 controls
whose weight was in the normal range [40]. In the study
reported here, there was no significant association with
obesity in Mexican-American participants in the GENOA
cohort who were ascertained as members of families with
at least two siblings with diabetes. The high percentage of
obese individuals (49.1%) (Table 1) and an average BMI
of 30.82 kg/m2 are consistent with expectation since obes-
ity is a well-established risk factor for diabetes in this pop-
ulation [58]. An association between the INSIG2
polymorphism and obesity both in unrelated and family
based samples was described by Herbert et al. for African-
Americans from Maywood, Illinois [19], but was not con-
Table 1: INSIG2 allele and genotype frequencies in case and comparison groups stratified by race and cohort
n HW
(p1)
q^
(%)
Obese
(n)
(%) GC
n
(%)
CG
n
(%)
CC
n
(%)
Non-
Obese
(n)
(%) GC
n
(%)
CG
n
(%)
CC
n
(%)
(p2)
ARIC
Afr.-Am.
3,870 0.80 24.8 1,570 40.6 910
(57.9)
563
(35.9)
97
(6.2)
2,300 59.4 1,281
(55.7)
875
(38.0)
144
(6.3)
0.36
CARDIA
Afr.-Am.
1,887 0.14 25.6 321 17.0 184
(57.3)
113
(35.2)
24
(7.5)
1,566 83.0 873
(55.7)
581
(37.1)
112
(7.2)
0.81
GENOA
Afr.-Am.
1,731 0.15 25.8 859 49.6 464
(54.0)
350
(40.8)
45
(5.2)
872 50.4 477
(54.7)
356
(38.5)
59
(6.8)
0.32
ARIC
White
10,696 0.61 33.2 2,430 22.7 1,099
(45.2)
1,070
(44.0)
261
(10.8)
8,266 77.3 3,689
(44.6)
3,649
(44.2)
928
(11.2)
0.76
CARDIA
White
2,001 0.34 33.8 142 4.4 59
(41.5)
65
(45.8)
18
(12.7)
1,859 95.6 828
(44.6)
811
(43.6)
220
(11.8)
0.78
GENOA
White
1,421 0.06 31.6 647 45.5 302
(46.7)
290
(44.8)
55
(8.5)
774 54.5 348
(44.9)
355
(45.9)
71
(9.2)
0.78
Ottawa
Cohort 1
White
754 0.57 33.5 380 50.4 176
(46.3)
164
(43.2)
40
(10.5)
374 49.6 161
(43.1)
165
(44.1)
48
(12.8)
0.51
Ottawa
Cohort 2
White
748 0.82 32.2 371 49.6 175
(47.2)
155
(41.8)
41
(11.0)
377 50.4 168
(44.6)
174
(46.1)
35
(9.3)
0.44
GENOA
Hispanic
1,614 0.43 26.6 793 49.1 421
(53.1)
313
(39.5)
59
(7.4)
821 50.9 456
(55.5)
304
(37.0)
61
(7.5)
0.58
Afr.-Am., African-American; n, number; HW, Hardy-Weinberg equilibrium; q^, frequency of the INSIG2 rs7566605 C allele; p1, p-value for chi-
squared goodness-of-fit test for Hardy-Weinberg equilibrium; p2, p-value Pearson chi-squaredPage 5 of 9
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Table 2: Association of INSIG2 rs7566605 CC genotype and obesity (BMI ≥ 30) stratified by cohort and race
Obesity
OR*
(95%
CI)
p*1 p2 BMI
(± SD)
GG/CG
BMI
(± SD)
CC
p*3 p4 Age
Obese
(± SD)
yrs
Age
Non-
Obese
(± SD)
yrs
Males
Obese
(%)
Males
Non-
Obese
(%)
ARIC
Afr.-Am.
1.02 0.78–1.34 0.89 29.60
(6.15)
29.94
(5.90)
0.25 53.38
(5.75)
53.58
(5.90)
26 45.9
CARDIA
Afr.-Am.
1.01 0.64–1.62 0.95 25.41
(5.89)
25.80
(5.65)
052 25.51
(3.72)
24.20
(3.81)
25.2 44.8
GENOA
Afr.-Am.
0.79 0.53–1.20 0.27 30.88
(6.62)
31.28
(6.69)
0.13 57.04
(10.23)
58.26
(10.43)
19.7 42.1
ARIC
White
0.95 0.82–1.10 0.50 27.03
(4.87)
26.86
(4.86)
0.25 54.42
(5.65)
54.36
(5.74)
46.1 47.6
CARDIA
White
1.07 0.64–1.79 0.80 23.73
(4.02)
23.84
(4.73)
0.70 25.94
(3.34)
25.53
(3.37)
40.1 47.6
GENOA
White
0.92 0.63–1.32 0.64 30.40
(6.35)
29.72
(5.27)
0.24 54.74
(10.70)
55.63
(11.13)
44.5 46.6
Ottawa
Cohort 1
White
0.79 0.50–1.24 0.30 NA NA - 46.27
(10.23)
45.57
(12.97)
37.1 36.4
Ottawa
Cohort 2
White
1.17 0.72–1.92 0.53 NA NA - 48.37
(10.46)
45.92
(16.29)
19.1 41.4
GENOA
Hispanic
0.94 0.64–1.38 0.74 30.90
(6.21)
29.92
(4.97)
0.03 52.77
(11.79)
56.99
(11.79)
34.2 47.6
Combined
Studies
0.96 0.86–1.06 0.38 27.85
(5.87)
27.30
(5.43)
0.15
Afr.-Am., African-American; OR, odds ratio; CI, confidence interval; BMI, body mass index; SD, standard deviation; *adjusted for age and sex; yrs, 
years; NA, not applicable; p1, p-value for multivariable logistic regression, referent group is comprised of individuals in study population with 
combined GG and CG genotypes (recessive model); p2, p-value for analysis of combined study population; p3, p-value for analysis of mean 
differences among INSIG2 rs7566605 genotypes using a general linear model; p4, p-value for analysis of mean differences in BMI among rs7566605 
genotypes using a general linear model and adjusting for age, gender, race, and study in the combined study population
Table 3: Association of INSIG2 rs7566605 CC genotype and anthropometric measures stratified by cohort and race
n Weight
(± SD)
GG/CG
Weight
(± SD)
CC
p* p1 Waist
(± SD)
GG/CG
Waist
(± SD)
CC
p* p1 Waist-to-
Hip Ratio
(± SD)
GG/CG
Waist-to-
Hip Ratio
(± SD)
CC
p* p1
ARIC
Afr.-Am.
3,869 83.36 (17.47) 85.31 (17.46) 0.12 99.02
(15.20)
100.79
(14.37)
0.06 0.918
(0.076)
0.932
(0.072)
0.01
CARDIA
Afr.-Am.
1,885 72.96 (18.02) 73.48 (16.68) 0.73 78.48
(12.40)
79.40
(11.35)
0.41 0.774
(0.067)
0.778
(0.062)
0.36
GENOA
Afr.-Am.
1,731 88.04
(18.70)
85.33
(17.01)
0.10 103.11
(16.50)
101.49
(17.09)
0.44 0.911
(0.076)
0.916
(0.083)
0.61
ARIC
White
10,690 77.13 (16.34) 76.71 (16.14) 0.32 96.31
(13.42)
95.68
(13.34)
0.08 0.929
(0.079)
0.925
(0.079)
0.04
CARDIA
White
1,997 69.91 (14.45) 70.24 (16.72) 0.60 77.18
(10.56)
77.59
(12.28)
0.43 0.779
(0.074)
0.782
(0.074)
0.17
GENOA
White
1,418 86.85
(19.96)
84.64
(17.19)
0.45 100.35
(15.80)
98.56
(13.30)
0.37 0.914
(0.092)
0.908
(0.088)
0.88
GENOA
Hispanic
1,613 82.05
(17.75)
80.01
(15.54)
0.11 106.77
(14.47)
106.03
(12.33)
0.55 0.975
(0.088)
0.984
(0.067)
0.17
Combined
Studies
23,203 79.04
(17.8)
77.83
(17.04)
0.32 95.21
(16.24)
94.28
(15.49)
0.38 0.902
(0.098)
0.903
(0.096)
0.74
Afr.-Am., African-American; n, number; SD, standard deviation; *adjusted for age and sex; p, p value for analysis of mean differences in 
anthropometric measures among INSIG2 rs7566605 genotypes using general linear model; p1, p-value for
analysis of mean differences in anthropometric measures among INSIG2 rs7566605 genotypes using a general linear model and adjusting for age, 
gender, race, and study after combining participants from all three cohorts
BMC Medical Genetics 2009, 10:56 http://www.biomedcentral.com/1471-2350/10/56firmed in a later study in the same population [20]. There
was no replicated association for the INSIG2 variant and
either obesity or BMI observed for African-American par-
ticipants in the ARIC, CARDIA, or GENOA studies.
The influence of INSIG2 rs7566605 on variation in other
anthropometric measures including weight, waist circum-
ference, and waist-to-hip ratio was also analyzed. There
were no significant mean differences observed among
INSIG2 rs7566605 genotypes except for an association
with waist-to-hip ratio for white and African-American
ARIC study participants. Although BMI is a widely used
surrogate measure of adiposity, waist-to-hip ratio is an
index of abdominal obesity and has been shown to be a
better predictor of both myocardial infarction and stroke
[59,60]. However, the difference in the direction of effect
observed for the two racial groups, and the marginal p-val-
ues given the large number of statistical tests conducted
make this result difficult to interpret, particularly in the
absence of direct measures of body composition. In addi-
tion, a combined analysis of all study participants
adjusted for age, gender, race, and study did not show a
significant association between the INSIG2 rs7566605
variant and waist-to-hip ratio (Table 3).
There are a variety of possible reasons to explain the dif-
ferent associations detected between the INSIG2 variant
and obesity in different populations. These include differ-
ences in ascertainment or study design, population sub-
structure, genotype call rate, degree of LD between
rs7566605 and a true causative variant, and heterogeneity
between the populations due to unknown genetic, life-
style, or environmental factors. In this context, a potential
interaction between the INSIG2 polymorphism and level
of physical activity was observed in the Danish Inter99
cohort. Study participants who were carriers of either the
rs7566605 C allele or G allele and were physically inactive
had a BMI that was 1.00 kg/m2 or 0.54 kg/m2 higher,
respectively, than their physically active counterparts with
the same genotype [52]. An additional reason for the fail-
ure to replicate an association between the INSIG2 genetic
variant and measures of obesity could be low statistical
power. In this study, there was adequate power (≥ 80%)
to detect an association similar to that reported in earlier
studies for the risk of obesity under a recessive genetic
model (OR = 1.29–1.75) [19,20,40,42] for each of the
racial groups within the ARIC and GENOA cohorts, while
the ORs detectable for white and African-American partic-
ipants in the CARDIA study were 1.96 and 1.87, respec-
tively. For all of the obesity-related continuous traits, the
power reached 95% to observe a small effect of the
INSIG2 sequence variant (R2 ≤ 1%) given the INSIG2
rs7566605 minor allele frequencies found for each study
population after stratification by race.
In the initial report describing the association between
INSIG2 and obesity, the lack of replication in the Nurses'
Health Study was attributed to the presence of fewer indi-
viduals with a high BMI when compared to the Framing-
ham Heart Study or KORA samples in which an
association between the rs7566605 variant and obesity
was observed [19]. In the case of the white ARIC partici-
pants, the BMI distribution appears to be comparable to
that of the KORA cohort. It was later suggested that the
effect of INSIG2 variation may be more prominent in
cohorts of young individuals [20]. Therefore, it is note-
worthy that we did not observe an association between
rs7566605 and BMI in the young CARDIA cohort. In sum-
mary, the results of an analysis of a sample of 24,722 indi-
viduals belonging to four cohorts do not support a major
role for the INSIG2 rs7566605 variant as a determinant of
obesity risk.
Conclusion
The results of this analysis of the influence of rs7566605
in a racially and ethnically diverse sample of 24,722 par-
ticipants drawn from two community based cohort stud-
ies, a family-based study, and a case-control study do not
support a major role for the INSIG2 polymorphism in
obesity risk.
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